Related references
Note: Only part of the references are listed.Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia
Bradley A. McGregor et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Busulfan and Cyclophosphamide (Bu/Cy) as a Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma: A Single-Institution Experience
Matthew Ulrickson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG
M. G. Martin et al.
BONE MARROW TRANSPLANTATION (2009)
Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: Analysis of Graft Sources and Long-Term Outcome
Michael B. Tomblyn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS
Borje S. Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia
John Moore et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Discovery and development of clofarabine: a nucleoside analogue for treating cancer
Peter L. Bonate et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia
S Jeha et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)
M Aoudjhane et al.
LEUKEMIA (2005)
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome
C Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clofarabine in adult acute leukemias: Clinical success and pharmacokinetics
T Cooper et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2004)
Dose modification protocol using intravenous busulfan (busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies
CB Williams et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2004)
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
M de Lima et al.
BLOOD (2004)
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
M de Lima et al.
BLOOD (2004)
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
H Kantarjian et al.
BLOOD (2003)
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells
M Bornhäuser et al.
BLOOD (2003)
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers
HM Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation
GB McDonald et al.
BLOOD (2003)
Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway
D Genini et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
